BDSX · Biodesix Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $88.50M | $71.32M | $49.09M | $38.21M | $54.51M | $45.56M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $12.00M | $9.56M | $9.99M | $13.10M | $12.79M | $10.82M |
| SG&A | $87.55M | $80.45M | $67.39M | $61.46M | $50.52M | $34.86M |
| Total Operating Expenses | $116.37M | $105.82M | $90.43M | $88.80M | $95.45M | $68.49M |
| D&A | $5.67M | $5.77M | $3.33M | $3.60M | $3.18M | $2.90M |
| Operating Income | ($27.87M) | ($34.50M) | ($41.34M) | ($50.59M) | ($40.94M) | ($22.93M) |
| Interest Expense | $7.72M | $8.26M | $9.54M | $8.07M | $4.51M | $7.60M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($35.27M) | ($42.93M) | ($52.15M) | ($65.45M) | ($43.16M) | ($31.35M) |
| EPS - Basic | ($4.67) | ($6.60) | ($12.80) | ($31.00) | - | - |
| EPS - Diluted | ($4.67) | ($6.60) | ($12.80) | ($31.00) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $18.99M | $26.25M | $26.28M | $43.09M | $32.71M | $62.13M |
| Accounts Receivable | $9.04M | $8.60M | $7.68M | $5.07M | $3.66M | $15.30M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $3.08M | $2.19M | $2.93M | $1.69M | $1.66M | $8.96M |
| Current Assets | $32.52M | $39.48M | $39.68M | $53.33M | $43.61M | $86.14M |
| Total Assets | $87.48M | $97.24M | $99.10M | $92.91M | $76.10M | $121.07M |
| Current Liabilities | $17.44M | $14.32M | $33.42M | $22.84M | $28.96M | $32.13M |
| Long-term Debt | $50.01M | $40.03M | $40.08M | $30.13M | $10.07M | $28.08M |
| Total Liabilities | $89.94M | $76.37M | $94.52M | $72.30M | $56.37M | $79.90M |
| Stockholders' Equity | ($2.46M) | $20.88M | $4.58M | $20.61M | $19.73M | $41.17M |
| Retained Earnings | ($497.76M) | ($462.50M) | ($419.57M) | ($367.42M) | ($301.97M) | ($258.81M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($23.27M) | ($48.65M) | ($22.87M) | ($44.97M) | ($28.22M) | ($21.37M) |
| Investing Cash Flow | ($403.0K) | ($3.44M) | ($23.06M) | ($3.53M) | ($2.55M) | ($2.93M) |
| Financing Cash Flow | $16.42M | $52.05M | $29.13M | $58.88M | $1.26M | $81.13M |
| CapEx | $259.0K | $3.23M | $22.92M | $3.30M | $2.24M | $1.95M |
| Free Cash Flow | ($23.53M) | ($51.88M) | ($45.79M) | ($48.27M) | ($30.46M) | ($23.31M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -31.5% | -48.4% | -84.2% | -132.4% | -75.1% | -50.3% |
| EBITDA margin | -25.1% | -40.3% | -77.4% | -123.0% | -69.3% | -44.0% |
| Net margin | -39.8% | -60.2% | -106.2% | -171.3% | -79.2% | -68.8% |
| Free cash flow margin | -26.6% | -72.7% | -93.3% | -126.3% | -55.9% | -51.2% |
| FCF / Net income | 0.67 | 1.21 | 0.88 | 0.74 | 0.71 | 0.74 |
| R&D / Revenue | 13.6% | 13.4% | 20.3% | 34.3% | 23.5% | 23.7% |
| SG&A / Revenue | 98.9% | 112.8% | 137.3% | 160.8% | 92.7% | 76.5% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -40.3% | -44.1% | -52.6% | -70.4% | -56.7% | -25.9% |
| Return on equity | 1430.6% | -205.6% | -1138.6% | -317.6% | -218.8% | -76.2% |
| Return on invested capital | -46.3% | -44.7% | -73.1% | -78.8% | -108.5% | -26.2% |
| Liquidity | ||||||
| Current ratio | 1.86 | 2.76 | 1.19 | 2.34 | 1.51 | 2.68 |
| Quick ratio | 1.86 | 2.76 | 1.19 | 2.34 | 1.51 | 2.68 |
| Cash ratio | 1.09 | 1.83 | 0.79 | 1.89 | 1.13 | 1.93 |
| Leverage | ||||||
| Debt / Equity | -20.29 | 1.92 | 8.75 | 1.46 | 0.51 | 0.68 |
| Debt / Assets | 0.57 | 0.41 | 0.40 | 0.32 | 0.13 | 0.23 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -3.6x | -4.2x | -4.3x | -6.3x | -9.1x | -3.0x |
| Equity multiplier | -35.49 | 4.66 | 21.64 | 4.51 | 3.86 | 2.94 |
| Liabilities / Assets | 1.03 | 0.79 | 0.95 | 0.78 | 0.74 | 0.66 |
| Efficiency | ||||||
| Asset turnover | 1.01 | 0.73 | 0.50 | 0.41 | 0.72 | 0.38 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 37d | 44d | 57d | 48d | 24d | 123d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | 190.1x | 659.8x | 94.0x | - | - |
| P / S | 0.6x | 55.6x | 61.6x | 50.7x | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 24.1% | 45.3% | 28.5% | -29.9% | 19.6% | - |
| Revenue CAGR (3y) | 32.3% | 9.4% | 2.5% | - | - | - |
| Revenue CAGR (5y) | 14.2% | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 19.2% | 16.6% | 18.3% | -23.6% | -78.5% | - |
| Net income growth (YoY) | 17.9% | 17.7% | 20.3% | -51.6% | -37.7% | - |
| EPS growth (YoY) | 29.2% | 48.4% | 58.7% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 54.6% | -13.3% | 5.1% | -58.4% | -30.7% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | 355.8% | -77.8% | 4.5% | -52.1% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$88.50M totalDiagnostic Tests$79.20M · 89.5%
Development Services$9.30M · 10.5%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-4.69
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Services-Medical Laboratories
Comparing BIODESIX INC against the 5 most active filers in the same SIC group.